

MOLECULAR DOCKING STUDY AS THERAPEUTIC APPROACH FOR TARGETING CHOLECYSTOKININ IN PANCREATIC CANCER

OKTAVIAN ARYA PUTRA, TESIA AISYAH RAHMANIA*, EDITHA RENESTEEN

Faculty of Military Pharmacy, Republic of Indonesia Defense University, Bogor-16810, Indonesia

*Corresponding author: Tesia Aisyah Rahmania; *Email: tesiaaisyah4@gmail.com

Received: 02 Apr 2024, Revised and Accepted: 21 Jun 2024

ABSTRACT

Objective: The Cholecystokinin A receptor (CCK-ARs), also known as CCK1 receptor, is a type of G protein-coupled receptor that is primarily responsive to the hormone Cholecystokinin (CCK). CCK-ARs is one of the receptors characterized and validated to promote pancreatic cancer progression. Devazepide is a selective antagonist of the CCK-ARs. This study aims to find a potential ligand that has the most effective and representative interaction with cancer receptors, becoming a new therapeutic effect using molecular docking Molecular Operating Environment (MOE) with receptor code 7F8U.

Methods: We conducted an *in silico* study by docking candidate ligands with Cholecystokinin Receptor (CCKRs) using the MOE 2015 V.10 application. The ligands of choice come from natural ingredients such as curcumin, resveratrol, berberine, baicalein, dioscin, wogonin, and piperine. Validate the receptor with the Root mean Square Deviation (RMSD) value and docking results with the GIBBS S value.

Results: 6 compounds, such as curcumin, resveratrol, berberine, baicalein, wogonin, and piperine, were selected for docking as candidates to determine whether they have interactions with CCK-ARs. Based on the docking results, the Gibbs values obtained were -14.9522; -12.4566; -15.5033; -12.6961; -13.4234; -11,6130 joules/kg. mol, berberine is the compound with the lowest Gibbs energy, namely -15.5033 joules/kg. mol and is one of the strongest. The interactions that occur include Methionine A121-side chain donor, Methionine B121-side chain donor, asparagine A333-amine group and nitrogen atom, B333-amine group and nitrogen atom, Arginine A336-negative oxygen atom, and B336-negative oxygen atom.

Conclusion: Berberine which is a natural alkaloid, is suitable for devazepide, which is a positive control for ligand interactions when tethered to the CCKRs. This finding could be a potential new drug for pancreatic cancer. However, further studies, such as *in vitro*, *in vivo*, and clinical trials need to be conducted for ordering activity, safety, and safety of new drugs.

Keywords: Pancreatic cancer, CCK, Molecular docking, *In silico*, 7F8U, Berberine

© 2024 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>) DOI: <https://dx.doi.org/10.22159/ijap.2024v16i5.51027> Journal homepage: <https://innovareacademics.in/journals/index.php/ijap>

INTRODUCTION

One of the deadliest cancers in the world is pancreatic cancer. This cancer has increased in cases in the last 2 decades with very high morbidity and mortality rates. Smoking, a family history of chronic pancreatitis, advanced age, being a man, having diabetes mellitus, being overweight, and having helicobacter infection are all risk factors for this cancerous condition [1].

In the military world, pancreatic cancer has the greatest influence as a deadly disease for military personnel. Military personnel are at very high risk of developing pancreatic cancer up to 75% annually [2]. As well as something invisible the military's susceptibility to pancreatic cancer after occupational exposure to chemical carcinogens and tobacco use. In addition, exposure to tobacco due to smoking habits is very high among military personnel. Cigarette smoke, such as Polycyclic Aromatic Hydrocarbons (PAHs) and heavy metals, contribute to pancreatic cancer rates in military personnel [3].

Surgical resection is currently the most well-known and successful treatment for pancreatic cancer, even though it still frequently manifests later than expected. Therefore, currently, the latest treatment derived from natural ingredients for cancer is being developed because it is effective and lacks serious side effects. Through experimental research, the anticancer properties of natural products were examined in cases of lung, breast, colon, pancreatic, and prostate cancer. Curcumin, resveratrol, berberine, baicalein, dioscin, wogonin, piperine, and other natural substances are among those said to have anti-cancer potential. Additionally, it is established that this natural substance causes more cancer cells to undergo apoptosis than healthy cells do. Consequently, natural products will be crucial in developing innovative cancer therapies in the future [4].

Cholecystokinin (CCK) is one of the receptors characterized and validated to promote the development of pancreatic cancer. Pancreatic cancer cells, fibroblasts, and lymphocytes contain Cholecystokinin Receptor (CCKRs) [5]. In humans, pancreatic cancer has Subtypes of Cholecystokinin A receptor (CCK-ARs) and CCK-BRs, with one of the inhibitors associated with CCK-ARs being devazepide. Devazepide is an exceptionally potent and selective CCK-ARs antagonist [6]. CCK antagonists have been investigated as growth inhibitors in particular cancers [7]. Devazepide is the most powerful and selective CCKRs antagonist, with about 160-fold more affinity compared to the CCK-BRs, for the CCK-ARs [8].

The method used is molecular docking, which aims to find suitable ligands or drug candidates for CCK targets. The *in silico* structure-based technique known as molecular docking enables the discovery of novel medicinal compounds, the prediction of molecular interactions between ligands and targets, and the characterization of Structure-Activity Relationships (SARs) without previous knowledge of the chemical structure of other potential target modulators [9]. Molecular docking provides the benefit of allowing us to see the interactions between ligands. This research intends to identify candidates for multiple ligands that interact with the CCKRs in pancreatic cancer and have more activity than devazepide, having the potential to be created as innovative treatments for pancreatic cancer.

MATERIALS AND METHODS

Material

The receptor Data were downloaded from <http://www.rcsb.org>'s Protein Data Bank (PDB). Table 1 describes selected ligands generated from natural substances, including curcumin, resveratrol, berberine, baicalein, dioscin, wogonin, and piperine. Devazepide served as our positive control (fig. 1). The 3D structure of the chemical was retrieved from the PubChem database in SMILES format.




Fig. 1: Molecular structure of devazepide as the positive control

Table 1: Plant and ligand structures used for this study

| Plant | Ligand | Ligand structure | IUPAC name |
|-------------------------------|-------------|------------------|--|
| <i>Scutellariabaicalensis</i> | Baicalein | | 5,6,7-trihydroxy-2-phenylchromen-4-one |
| <i>Berberis vulgaris</i> | Berberine | | 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.0[2,10].0[4,8].0[15,20]]henicosa-1(13),2,4(8),9,14,16,18,20-octaene |
| <i>Curcuma longa</i> | Curcumin | | (1 <i>E</i> ,6 <i>E</i>)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
| <i>Piper nigrum</i> | Piperine | | (2 <i>E</i> ,4 <i>E</i>)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one |
| <i>Vitis vinifera</i> | Resveratrol | | 5-[(<i>E</i>)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol |
| <i>Tetracera indica</i> | Wogonin | | 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one |

Methods

Ligand and receptor docking

CCKRs determination in pancreatic cancer

Receptors and existing drugs are searched as positive controls associated with pancreatic cancer from Pubmed. The CCK PDB, RCSB was consulted for the receptor file with the identification code 7F8U. MOE tool is used to examine the structure of the receptor file with the code 7F8U. mbd extension [10, 11].

Preparation of receptors with validation

Protonation at the 7F8U receptor by adding a proton in the form of a hydrogen cation (H⁺ion) to the molecule to determine the gasteiger charge and polar bond for each atom in the molecule, as well as to correct the partial charge estimate. MOE conducted validation of the docking approach utilizing two determining the target protein's and its original ligand's RMSD value was used to validate the docking approach. RMSD is a measure used to determine the similarity between flexible and stiff crystallographic result interaction techniques and docking ligands [12]. The target protein is considered legitimate if the RMSD value is less than 2 [13].

Docking of the molecules to the receptors

Using the MOE software, parameters and data are acquired to establish the optimal ligand-receptor interaction, which is then

contrasted with positive controls and valid receptors with ligands [10, 11].

Analysis and visualization of docking results

Determination of the conformation of the docking ligand (best pose) is done by choosing conformational ligands that have bonded energies the lowest. Docking results with pose best then analyzed using Discovery Studio. Analyzed parameters include amino acid residues, hydrogen bonds, predictive inhibition constant, and free energy bonds. Determination based on bond-free energy is indicated by the docking result which has the most negative (*S*) value [10, 11].

In silico toxicity prediction

The toxicity prediction process begins with searching for the structure of the compound to be tested by entering the canonical SMILE structure using the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). ProTox II website ([Sttps://toxnew.charite.de/protox_II/index.php?site=compound_input](https://toxnew.charite.de/protox_II/index.php?site=compound_input)), Enter the canonical SMILE structure, select additional models for prediction including organ toxicity, endpoint toxicity, Tox21 Nuclear receptor signaling pathways, Tox21 Stress response pathways. The results are obtained in the form of LD50 levels and categorized into 5 types of LD50 levels.




RESULTS AND DISCUSSION

We performed ligand validation and docking procedures on several ligands, obtained the *S* value (Joule/kg. mol), and described the relationship between the ligand and the receptor. The free bond

energy value is determined as follows, it is found that the largest S value (Joule/kg. mole) is found in the natural compound berberine

with an S value of -15.5033, which has the following bond description.

Table 2: The result of CCK (7F8U) docking of the receptor with several ligands

| Ligand | ΔS (Joules/kg. mole) | Ligand and receptor interaction |
|-------------|------------------------------|---|
| Baicalein | -12,6961 |  → Cysteine 195 |
| Berberine | -15,5033 | NH ₃ → Asparagin A333 and Asparagin B333 N → Asparagin A333 and Asparagin B333 O → Arginin A336 and Arginin B336 Sidechain → Metionin A121 and Metionin B121 There is only ligand exposure and receptor exposure |
| Curcumin | -14,9522 | R=O → Phenilalanin 198 |
| Piperine | -11,6130 | Sidechai → Cysteine 94 |
| Resveratrol | -12,4566 | R-OH → Asparagin 98 |
| Wogonin | -13,4234 |  → Histidin 210 |
| | | R-OH → Histidin 210 |
| | |  → Asparagin 98 |

The following is an illustration of the interaction between potential ligands from natural products and the CCKRs (7F8U). It was found that the natural product berberine ligand had the most bonding interactions between the ligand and the receptor and the ΔS value was very dominant.




Fig. 2: Ligand interaction with CCKRs (7F8U), a). Baicalein, b). Berberine, c). Curcumin, d). Piperine, e). Resveratrol, f). Wogonin




Fig. 3: Formation of pancreatic cancer cells mediated by exogenous peptide gastrin and CCK at the CCK-BRs. The alkaloid berberine is an isoquinoline that has therapeutic potential. Berberine offers pharmaceutical uses such as those for treating cancer, oxidase, hyperglycemia, and Low-Density Lipoprotein production (LDL). Berberine dramatically slows the growth of HUVEC that is induced by LDL. As is known, oxLDL increases HUVEC proliferation by producing O₂ through the NAD (P) H oxidase. The result of the oxLDL-induced proliferative HEVECs is the inhibition of MAPKs via phosphorylation. MAPKs activate the ERK 1/2, p38MAPK, and ERK 5 signaling pathways. From the situation when ERK 1/2 and ERK 5's functions as growth, differentiation, and development will be hampered. In contrast, p38MAPK will be activated to initiate the processes of inflammation, apoptosis, cell proliferation, and differentiation. The MAPK p38MAPK inhibitor will increase apoptosis and inflammation in the pancreatic cancer subtype and inhibit gastrin peptide CCK-BRs. Cell is produced normally since the cancer cell has already degraded.

CCKRs is one of the receptors found and defined in pancreatic cancer; this receptor is overexpressed in pancreatic cancer. Signaling in pancreatic cancer is started when the CCKRs ligand gastrin or CCK is activated, which results in cell proliferation. In human pancreatic cancer, gastrin is overexpressed and has been discovered to accelerate growth through an autocrine mechanism. It is well known that in this case, pancreatic carcinogenesis and cancer development are primarily fueled by the CCK-BRs pathway. Gastrin and CCK peptides are generally synthesized in the duodenum and not in the pancreas [14].

CCK-A, which predominates in the normal murine pancreas, and CCK-B, which predominates in the normal human pancreatic, have been identified as the two kinds of CCKR. In normal human pancreatic tissue, the CCK-BRs phenotype serves as the primary receptor. Exogenous peptide gastrin and duodenal CCK go via the peripheral circulation and connect to the CCK-BRs to initiate intracellular signaling and release digesting pancreatic enzymes in the typical human pancreas. The CCK-BRs is overexpressed in pancreatic cancer, and cancer cells produce the peptide gastrin as a result. These circumstances drive cancer cells to secrete Gastrin-17, which binds to additional CCK-BRs and stimulates cell proliferation through an autocrine process [15].

Berberine is a naturally occurring isoquinoline alkaloid identified from *Coptis chinensis*, *Berberis aquifolium*, and *Berberis aristate*, among other therapeutic plants. In recent studies, berberine offers anti-tumor, anti-oxidation, anti-hyperglycemic, and LDL-lowering characteristics as well as other pharmaceutical purposes. In cancer, one of the key steps is to inhibit cell proliferation. Research has demonstrated that the alkaloid compound berberine, when used as a chemopreventive medication, can effectively target several tumors by altering various signaling pathways. Because of their restricted water solubility, numerous nanotechnological methods have been developed to aid in their dispersion across cell membranes. Two of the six clinical trials under investigation are already complete [16]. By inhibiting the expression of PCNA, NF- κ B, and LOX-1, Berberine dramatically inhibits the proliferation of oxLDL-induced HUVECs. As is well known, oxLDL enhances HUVEC proliferation via NAD(P)H oxidase-derived O₂ production. The result of oxLDL-induced inhibition of HEVECs proliferation is suppression of MAPKs phosphorylation. MAPKs produce signals in the form of ERK 1/2,

p38MAPK, and ERK 5. Of the three forms of signaling, conditions are generated where the work of ERK 1/2 and ERK 5 will be inhibited from carrying out their functions as growth, differentiation, and development. Meanwhile, p38MAPK will be induced to carry out its function in the form of inflammatory processes, apoptosis, growth, and differentiation. Ultimately, signaling MAPKs p38MAPK will induce apoptosis and inflammation in pancreatic cancer cells and inhibit gastrin peptides against CCK-BRs. Normal cells are produced because cancer cells have been degraded [17].

7F8U was selected to be the receptor used for docking in this study which was taken from the RCSB PDB. CCKARs-lintitript, CCKARs-devazepide, and CCKARs-NN9056 structures' atomic coordinates have been submitted to the PDB RCSB with the corresponding accession numbers 7F8U, 7F8Y, and 7F8X, respectively [18]. CCKRs selection is based on the percentage value of positive tumors in pancreatic cancer of 67 to 100; CCKRs-positive tumors are often characterized by neuroendocrine differentiation, as assessed by immunohistochemical synaptophysin [19]. Devazepide (L-364.718) was used as a positive control which was used as a comparison to determine the active constituent (ligand). The selective CCKRs antagonist devazepide (L-364.718) suppresses the growth of human pancreatic cancer cell lines, according to research [20].

Preparation and validation of 7F8U

Preparation of 7F8U protein by separating the protein from the native ligand so that there is space (pocket/cavity) that will be used during the berberine docking process on the protein. The result of this protein preparation process is a protein without the original ligand and the original ligand which is saved in the form of a pdb file.

Docking the 7F8U back via a 3D protonation procedure utilizing the moe program served to validate the molecular docking approach. The validation parameter of the method used is the RMSD value. It compares the atomic locations between the experimental structure and the structure docked to the protein to measure two postures. The method is considered valid if the resulting RMSD 2 value is valid [22]. The lesser the RMSD number, the higher the quality of predicted ligand conformation will be since it will be closer to the original conformation [23].




Fig. 4: Agonist and antagonist inhibitor for CCKRs. The neurointestinal peptide hormone receptors known as CCKARs and CCKBRs for CCKplay a significant role in the control of appetite and food intake. Here, we provide two CCK-BRs-gastrin cryo-electron microscopy structures in complex with Gi2 and Gq, as well as three crystal structures of human CCKARs in complex with various ligands, including one peptide agonist and two small molecule antagonists. The molecular underpinnings of peptide selectivity in the CCKRs family are revealed by this structure, along with the pattern recognition of various types of ligands. Our findings offer atomic insights for various receptor activation and ligand recognition pathways when combined with pharmacological information. These understandings will aid in the identification of possible treatments that target the CCKRs [21]

Docking of several compounds with CCKRs (7F8U)

Docking ligands on the active site of the CCK 7F8U receptor using the Moe 2015.10 program with induce fit refinement settings with a minimum of 20 poses. In the form of the bond energy value between the receptor and ligand, the docking procedure predicts the interaction activity between the ligand and receptor. According to the Gibbs energy hypothesis, the binding between a ligand and its receptor is more stable, the less energy is created during the bonding process. The bond energy shows the affinity between cyanidin and peonidin with the protein; the lower the bond energy obtained, the more stable the bond formed [24].

The outcome of the docking method is a prediction of the interaction activity between the ligand and the receptor. The process of molecular docking facilitates the determination of the binding geometry between two molecules that interact and have known structures. The process of docking foretells the ideal alignment of the ligand and receptor to form a stable complex [25]. Six compounds were chosen as candidates for docking to evaluate if they interact with the CCKRs. Based on the outcomes of the docking, the free energy values of 8 compounds, baicalein, berberine, curcumin, piperine, resveratrol, and wogonin were -12.6961, respectively; -15.5033; -14.9552; -11.6140; -12.4566; -13.4234. This value is formed due to several interactions with receptors such as side chain donors for Methionine A121 and B121, asparagine A333 and B333 with amine groups and nitrogen atoms, Arginine A336 and B336 with negative oxygen atoms, cysteine 195 with benzene, and so on. However, of the 6 compounds, some compounds do not have direct interactions, such as curcumin. Curcumin has only ligand-exposed and receptor-exposed areas. This implies that the ligand does not interact with the protein's active site [26].

Of the 6 ligands that were successfully attached to the 7F8U receptor, the ligand compound with the strongest interaction was berberine because it had a free energy Gibbs S value of -15.5033 Joule/kg. Mole. Occurs due to several interactions with receptors such as side chain donors for Methionine A121 and B121, asparagine A333 and B333 with amine groups and nitrogen atoms, and Arginine A336 and B336 with negative oxygen atoms. One of the berberine factors has the highest S value due to the presence of hydrogen bonds. The strongest dipole-dipole force occurs in hydrogen bonds, which are the connections that connect hydrogen atoms in one molecule to other elements (N, O, and F) in other molecules [27]. In addition, according to Prananto, hydrogen bonds are electrostatic interactions between atoms that are hydrogen bonded to each other's electronegative atoms [28]. Meanwhile, Kurniawan and Nur claim that protons' dynamic movements inside a bond are properties of hydrogen bonds' constituent protons [29]. These molecular interactions with one another, which produce hydrogen bonds, typically take the appearance of hard-to-see dashes. The

creation of newly established bonds hydrophobic interaction, the Van Der Waals forces, and the amount of hydrogen in the container all have an impact on energy [30, 31]. The more complex the compounds with interacting proteins are, the lower the bond energy formed and the stronger the bond between the two [31-36]. The Gibbs S free energy value of berberine compounds is more negative than that of devazepide. The more negative the Gibbs energy value, the stronger hydrogen bond [31-37]. Therefore, the berberine compound became a comparable compound with positive control among all docking ligands. Berberine is the primary isoquinoline alkaloid isolated from the traditional Coptis plant, and it has a variety of pharmacological properties, including antimicrobial, antidiabetic, and anti-inflammatory. Berberine has a positive therapeutic impact on cancer by adjusting the apoptotic and signal transduction pathways' activity, eventually slowing the proliferation of malignant cells. Moreover, A topoisomerase II (topology II) inhibitor called berberine may prevent the production of topoisomerase-mediated Splicing complexes for DNA, hence influencing the DNA autonomic replication process to trigger tumor cell death [38].

Toxicity prediction of berberine compound

The scoring was to identify potential lead compounds. The binding affinities were compared with known anticancer drugs, devazepide. The interaction analysis between ligand and protein active site residue identified vital interactions. The structure-activity relationship was done by comparing the compound's chemical structure with predicted activity. Virtual ADME analysis was done using ADME software, and the values were compared [39]. Promising binding energy to the target receptor is not the only criterion for promising drug candidates. The secret to success in drug development is comprehending a drug candidate's entire mechanism of action within the human body. Furthermore, toxicity analysis of possible drug candidates is crucial for the preliminary assessment of a medicine's potential hazard to humans. Researchers can screen medication candidates more quickly and effectively by using a computer to analyze toxicity, which reduces the time and expense associated with the research and development phases. Additionally, this information may steer the development of safer and more effective drug candidates and assist prevent clinical trial failures. The overall results of the toxicity analysis show that berberine is very safe to use orally and in inhalation. However, you need to be careful about using berberine directly on the skin, especially for people who have sensitive skin, because it might cause an allergic reaction. Apart from that, the Bolied-egg diagram shows that berberine can penetrate well into the BBB as indicated by the location of berberine in the yellow area. From these results, berberine has the potential to be a safe and effective drug candidate in all drug administration routes that works as a trigger for apoptosis and cell death through the CCKRs which can be useful for pancreatic cancer sufferers.




Fig. 5: Penetration ability in the Blood Brain Barrier (BBB) and toxicity value of berberine




Fig. 6: In silico toxicity prediction with ProTox II website

Based on the type of compound, method of administration, and type of organism, the LD50 value of berberine varies greatly. In the predicted results of the oral toxicity test using the ProTox-II application, the predicted LD50 of the berberine compound was 200 mg/kg. These results show that the predicted level of toxicity of the

berberine compound in the predicted oral toxicity test is at level 3, where the conclusion is that this berberine compound is likely to be of the moderately hazardous type ($50 < LD50 \leq 300$).

This is also explained further in the following table.

Table 3: Globally harmonized system of classification and labelling of chemicals (GHS) and WHO guidelines of chemical hazardous

| LD ₅₀ (mg/kg) | ≤ 5 | 5-50 | 50-300 | 300-2000 | 2000-5000 | > 5000 |
|--------------------------|-----------------------------|--------------------------|------------------------------|------------|-----------------------------|-----------------------|
| GHS | Category 1 | Category 2 | Category 3 | Category 4 | Category 5 | Category 6 |
| WHO guidelines | Ia (extremely hazardous) | Ib (Highly hazardous) | II (moderately hazardous) | | III (Slightly hazardous) | IV (Non-hazardous) |

Chemical hazards are divided into four classifications according to the WHO's 1978 classification guidelines: Class Ia (very hazardous), Class Ib (very hazardous), Class II (moderately hazardous), Class III (somewhat hazardous), and Class IV (non-hazardous). These guidelines have periodically been updated and republished. International criteria for chemical categorization and labeling are provided by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO). Significant national roles are played by these voluntary recommendations, particularly in developing nations. For the GHS to be implemented, the agricultural sector is essential, and both organizations are thinking about aligning the classification of industrial chemicals with pesticides. The FAO Guidelines must be updated before the WHO Guidelines, nevertheless. GHS was included in the 2009 WHO Guidelines update. The revised recommendations included both acute and chronic toxicity, particularly for active components, and eliminated the distinction between classification criteria for liquids and solids. They also kept the previous WHO Classes. For instance, the WHO categorized captafol as extremely dangerous due to its carcinogenicity in rats and mice, despite the drug being classed as GHS Category 5 for acute oral toxicity [40].

Under the GHS, the toxicologist (or ecotoxicologist) will continue to play a crucial role in the current chemical hazard classification systems. Toxicologists are in charge of creating the data (*in vitro* tests, ecotoxicological and toxicological research) that will be utilized in the classification process. They are also crucial in the interpretation of that data. When the data meets the numerical criteria specified in the GHS,

categorization may be necessary for specific hazard endpoints, and it won't take much expertise to determine that classification. For instance, a chemical that causes acute toxicity in rats and has an approximate oral LD50 of 200 mg/kg will be classified as category 3. Substances and mixtures are categorized according to the entire "weight of evidence," which takes into account data from animal experiments, human experience, and *in vitro* testing. This holds for all danger classifications, including irritancy and skin corrosivity. For example, data from animal research, human studies, *in vitro* testing, and pH information can all be used to determine the proper classification. Using this weight of evidence method, the toxicologist's judgment is needed to decide the proper classification. Since single animal studies frequently yield insufficient data, the weight of evidence technique is essential for classifying chemicals for carcinogenicity, germ cell mutagenicity, or reproductive toxicity. Studies on the site and manner of action are combined with data from *in vitro* experiments, animal experiments, and human experience. The key is expert toxicological judgment. Because of worries about animal cruelty, the use of validated *in vitro* tests in hazard classification is expanding. To classify compounds or combinations using the weight of evidence methodology, a data package is utilized to assess the robustness of the methodologies that toxicologists have developed and researched [41].

Cardiotoxicity, cytotoxicity, genotoxicity, mutagenicity and carcinogenicity

Berberine appears to have several pharmacological properties, including immunomodulatory, antioxidative, cardioprotective,

hepatoprotective, and renoprotective actions, according to numerous clinical and experimental research [42]. In addition, it has been proven that berberine has an inhibitory effect on the potassium rectifier current so that it delays and the hERG coating increases the action potential, which can have antiarrhythmic and arrhythmogenic properties. Berberine vulgaris showed a positive impact on heart contractility, blood pressure reduction, and protection against reperfusion injury [43]. Several studies have also reported that berberine is a good antitumor in both *in vitro* and *in vivo* tests; therefore, it is called a valuable anticancer drug. Berberine has a certain level of toxicity in normal cells, which has the basic mechanism of inhibiting adenine nucleotide translocase which is followed by a decrease in energy production. One of them is berberine in 10 mmol, which can induce the most toxic potential after 2 h of treatment; this compound increases oxidative stress and reduces nerve viability [44].

It has been demonstrated that berberine benefits both healthy and malignant cells *in vivo*. Berberine was discovered to decrease tumor multiplicity in a mouse model of colorectal carcinogenesis in a study conducted in 2015 by Li and colleagues. In a different study, mice were given injections of SiHs cells to assess the impact on tumor growth and lung metastasis. Treatment with berberine reduced lung metastasis, pulmonary weight, tumor size, and angiogenesis. It exhibited mild inhibitory effects on tumor development and weight in a 4T1 breast cancer model in mice. Anti-DR5 and berberine

together enhanced their antitumor effects and decreased the occurrence of lung metastases. Additionally, berberine therapy reduced the size and growth of tumors created by implanting S 180 sarcoma tumor cells into Kunming mice as well as prostate cancer PC-3 and LNCaP cells into BALB/c athymic mice. Goldenseal contains berberine, which has been shown to cause double-strand breaks in cells lacking Rev3. The comet assay test demonstrates that via blocking topoisomerase 1, raising histone H2A. X phosphorylation, inducing cell cycle arrest, and activating checkpoint-related proteins, berberine, and goldenseal causes DNA damage in HeLa and HepG2 cells. In haploid yeast cells grown in non-growth circumstances, berberine chloride is nonmutagenic; yet, in dividing cells, it increases the frequency of cytoplasmic PETITE mutations and HOM3 frameshift reverts. One could classify berberine's phototoxicity as genotoxicity. Berberine causes photodamage to the eyes and increases the risk of illnesses affecting the lens epithelial cells when it is used in eye drops and lotions. When human HaCaT keratinocytes are exposed to UVA radiation at a concentration of 50 μ M, berberine results in an 80% reduction in cell viability and single-strand breaks in DNA. It's noteworthy to note that berberine's phototoxicity depends on its solvent. In nonpolar solvents like CH_2Cl_2 , berberine radiation produces both O_2 and radical species, but not in aqueous solutions. It is important to take UVA protection into account when using berberine topical treatment [43, 45].

Table 4: A collection of previous *in vitro* studies that tested the berberine compound on the target of several cancer cell lines so that it can become a reference for further studies

| Model | Treatment berberine | Effects to cell | Mechanism action | Reference |
|---|--|--|---|-----------|
| BxPC-3 | 10–200 μ M berberine 24–72 h | ↓ Proliferation | ↑ Caspase 3/7 | [46] |
| PANC-1 | 0.3–6 μ M berberine 17–72 h | ↓ Proliferation | ↑ pAMPK (Thr172) | [47] |
| MiaPaCa-2 | | ↑G1-phase population ↓S and G2/M-phase population ↓Mitochondrial membrane potential ↓ ATP levels | ↑ pACC (Ser79) ↓ mTORC1 ↓pp70 S6K (Thr389) ↓ pS6 (Ser240/244) ↓pERK (Thr202/Tyr204) ↑ pRaptor (Ser792) | |
| Mia-PaCa-2 PANC-1 | 15 μ M berberine 72 h | ↓ CSC population | ↓ SOX2 ↓ OCT4 ↓ NANOG | [48] |
| PANC-1 Mia- PaCa-2 | 1–15 μ M berberine 72 h | ↑G1-phase population ↓S-phase population ↑ Apoptosis ↑ ROS | ↑ Caspase-3/7 activity | [49] |
| Mia-PaCa-2 | 10–50 μ M berberine 1–48 h | ↓ Citrate synthase activity ↑G1-phase population ↓ S and G2-phase population ↑ Senescence ↓ Migration ↓ Invasion | ↑ p21 ↑ Caspase-3 activity ↑ LC3 ↑ DAP1 ↓ CXCR4 ↑ DNMT1 ↑ DNMT3A ↑ DNMT3B ↑ MGMT | [50] |
| Panc-1 | 1–60 μ M berberine 48–72 h | ↑ Apoptosis ↓ Metastasis ↑ Glycolysis-associated metabolites ↑ Glutamine-associated metabolites ↓ Citric acid cycle-associated metabolites ↑ Mitochondrial damage ↓ Citrate metabolism | ↓ TNF α ↓ CA242 ↓ K-Ras ↑ CDKN2A | [51] |
| PANC-1 AsPC-1 SW1990 | 0–30 μ M berberine 24 h | ↓ Trans-endothelial migration | ↓ pSmad2 ↓ pSmad3 ↓ SNAIL1 ↓ SLUG ↓ CK19 ↓ LDHA ↓ ALDOA ↓ PFKL ↓ PKM2 ↓ PDK1 ↑ pAMPK ↓ pmTOR ↓ HIF-1 α | [52] |
| TGF- β treated Primary acinar cells | ADM induction: 5 ng/ml TGF- β 2 Days 10 μ M berberine 1–2 d | ↓ ADM ↓ Glycolysis | ↑ pAMPK ↓ pmTOR ↓ HIF-1 α ↑ Cytochrome C ↑ AIF ↑ Apaf-1 ↑ Bax ↑ Cleaved Caspase-3 ↑ Cleaved PARP ↓ Bcl-2 | [53] |
| MIN6 | 2.5–50 μ M berberine 2–24 h | ↑ Apoptosis ↑ DNA fragmentation | ↑ Cytochrome C ↑ AIF ↑ Apaf-1 ↑ Bax ↑ Cleaved Caspase-3 ↑ Cleaved PARP ↓ Bcl-2 | [54] |

Literature study of *in vitro* analysis cells cultured of pancreatic cancer

High concentrations of berberine (10–200 μM) have been shown to inhibit the growth of pancreatic cancer cells and induce caspase-independent cell death in BxPC-3 human pancreatic adenocarcinoma cells and HPDE-E6E7c7 normal human pancreatic ductal epithelial cells. Berberine treatment significantly increased caspase-3 and-7 activity in both cell lines, suggesting that berberine induces apoptosis in cancer cells at high concentrations. Additionally, berberine induces apoptosis by mechanisms that do not require caspase. Berberine or lovastatin therapy decreased cell viability in a dose-dependent manner, and the combination of the two drugs had extremely advantageous cytotoxic and cytostatic effects. Pre-treatment with products of the mevalonic acid pathway decreased the anticancer effects of lovastatin but not berberine, indicating that berberine boosts the anticancer effects of lovastatin independently of the cholesterol synthesis process. After being exposed to berberine for 17–72 h, pancreatic cancer cells (PANC-1 and MiaPaCa-2) had reduced mitochondrial membrane potential and ATP levels, an increase in the number of cells in the G1 phase, and inhibition of DNA synthesis and proliferation. This was similar to the well-known inhibitor of mitochondrial complex I, metformin, which inhibits the growth of tumors. Moreover, berberine suppressed the activation of ERK and mTORC1 induced by insulin and neurotensin in a concentration-dependent manner. Furthermore, berberine decreased the proportion of side population (SP) cells in PANC-1 cells, downregulating genes associated with stem cells. After being exposed to 1–15 μM berberine for 72 h, PANC-1 and Mia-PaCa-2 pancreatic cancer cells showed increased G1 phase population, concentration-dependent reduction of cell growth, and activation of apoptosis. The notion that berberine's effects are ROS-dependent is suggested by the concentration-dependent increase in intracellular ROS levels that accompanied the compound's proapoptotic impact.

Berberine, a material found in the cytoplasm of MiaPaCa-2 cells, has been shown to suppress mitochondrial function and induce autophagy. Berberine treatment significantly decreased cell migration and invasion and enhanced the mRNA expression of DNA methyltransferases (DNMT) in wound-healing experiments. Furthermore, berberine therapy inhibited the growth of pancreatic cancer cells by lowering the expression of tumor necrosis factor α , carbohydrate antigen 242, and K-Ras, three oncogenic proteins. berberine elevated metabolites associated with energy metabolism and decreased metabolites associated with the citric acid cycle because it damaged mitochondria. Berberine therapy suppressed the viability of AsPC-1, PANC-28, and MIA-PaCa-2 pancreatic cancer cells and decreased their colony formation in a concentration-dependent manner. In MIA-PaCa-2 cells, a TP53 gain-of-function mutation results in the synthesis of a p53 protein with a modified DNA binding motif. It has been demonstrated that berberine has anticancer capabilities that could prevent the spread of pancreatic cancer cells by fortifying the pulmonary vascular barrier. By binding to TGFBR1, berberine inhibits its kinase activity, protecting the endothelium barrier. In one study, berberine decreased CK19 levels, increased amylase levels, and decreased the induction of ADM in cells treated with TGF- β . Furthermore, berberine attenuated the Warburg effect, permitting lactate production and glucose consumption to resume in acinar cells treated with TGF- β . berberine also increased activated levels of AMPK and decreased active mTOR and HIF-1 α . Compound C, an AMPK inhibitor, restored glycolysis and prevented berberine from inhibiting PanIN development. After berberine treatment, the number of apoptotic cells and pro-apoptotic chemicals increased, and concentration-dependent reductions in cell viability were seen in MIN6 insulinoma cells.

CONCLUSION

Berberine, which is a natural alkaloid, is suitable for devazepide, which is a positive control for ligand interactions when tethered to the CCKRs. This finding could be a potential new drug for pancreatic cancer. However, further studies, such as *in vitro*, *in vivo*, and clinical trials need to be conducted for ordering activity, safety, and safety of new drugs.

ACKNOWLEDGEMENT

This study was supported by the Republic of Indonesia Defense University, Bogor, Indonesia. We also thank the supervising lecturers who have guided us in the preparation of this journal.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

OA: Protein Preparation, Docking, Molecular Modelling, TAR: Analysis Data, Developed the Concept and Design Manuscript, ER: Helped Revised Manuscript

CONFLICT OF INTERESTS

There is no conflict of interest in this research

REFERENCES

- Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *Lancet*. 2011 Aug;378(9791):607-20. doi: 10.1016/S0140-6736(10)62307-0, PMID 21620466, PMCID PMC3062508.
- Sadr Azodi O, Oskarsson V, Discacciati A, Videhult P, Askling J, Ekblom A. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. *Am J Gastroenterol*. 2018 Nov;113(11):1711-9. doi: 10.1038/s41395-018-0255-9, PMID 30315287.
- Tuveson D. The early detection of pancreatic cancer in the U.S. military. *MD*; 2015 Oct.
- Kim A, Ha J, Kim J, Cho Y, Ahn J, Cheon C. Natural products for pancreatic cancer treatment: from traditional medicine to modern drug discovery. *Nutrients*. 2021 Oct 26;13(11):34836055. doi: 10.3390/nu13113801, PMID 34836055, PMCID PMC8625071.
- Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. *Cancer Immunol Immunother*. 2018 Feb 17;67(2):195-207. doi: 10.1007/s00262-017-2077-9, PMID 29043413, PMCID PMC5801048.
- Brown NJ, Rumsey RD, Read NW. The effect of the cholecystokinin antagonist devazepide (L364718) on the ileal brake mechanism in the rat. *J Pharm Pharmacol*. 1993;45(12):1033-6. doi: 10.1111/j.2042-7158.1993.tb07175.x, PMID 7908970.
- Lattmann E, Sattayasai J, Narayanan R, Ngoc N, Burrell D, Balaram PN. Cholecystokinin-2/gastrin antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anti-inflammatory analgesics for the treatment of inflammatory bowel disease. *Med Chem Comm*. 2017;8(3):680-5. doi: 10.1039/c6md00707d, PMID 30108786, PMCID PMC6072330.
- Offel M, Lattmann P, Singh H, Billington DC, Bunprakob Y, Sattayasai J. Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-ones and their evaluation as cholecystokinin-ligands. *Arch Pharm (Weinheim)*. 2006 Apr 6;339(4):163-73. doi: 10.1002/ardp.200500217, PMID 16572480.
- Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. *Int J Mol Sci*. 2019 Sep 4;20(18):31487867. doi: 10.3390/ijms20184331, PMID 31487867, PMCID PMC6769923.
- Baihaki MF, Wardhani BW, Renesteen E, Rahmania TA. Candidates targeted therapy of epidermal growth factor receptor for lung cancer: in silico study. *J Southwest Jiaotong Univ*. 2021 Dec 24;56(6):948-58. doi: 10.35741/issn.0258-2724.56.6.83.
- Harahap A, Rahmania T, Renesteen E, Wardani B. In silico study: molecular docking targeting KRAS Receptor In Lung Cancer. *Az Med J*. 2022 Nov;62(09).
- Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW. Validation of molecular docking programs for virtual screening against dihydropteroate synthase. *J Chem Inf Model*. 2009 Feb 23;49(2):444-60. doi: 10.1021/ci800293n, PMID 19434845, PMCID PMC2788795.
- Ruswanto R, Mardhiah M, Mardianingrum R, Novitriani K. Synthesis and in silico study of the compound 3-nitro-N'-[(pyridine-4-yl) carbonyl]benzohydrazide as an antituberculosis candidate. *Chim Nat Acta*. 2015 Aug 12;3(2):n2.9183.14. doi: 10.24198/cna.v3.n2.9183.
- Smith JP, Fonkousa LK, Moody TW. The role of gastrin and CCK receptors in pancreatic cancer and other malignancies. *Int J Biol*

- Sci. 2016;12(3):283-91. doi: 10.7150/ijbs.14952, PMID 26929735, PMCID PMC4753157.
15. Fino KK, Matters GL, McGovern CO, Gilius EL, Smith JP. Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. *Am J Physiol Gastrointest Liver Physiol.* 2012 Jun 1;302(11):G1244-52. doi: 10.1152/ajpgi.00460.2011, PMID 22442157, PMCID PMC3378167.
 16. Mehdi S, Chauhan A, Dhutty A. Cancer and new prospective to treat cancer. *Int J Curr Pharm Sci.* 2023 Nov 15:16-22. doi: 10.22159/ijcpr.2023v15i6.3078.
 17. Xu RX, Sun XC, Ma CY, Yao YH, Li XL, Guo YL. Original article impacts of berberine on oxidized LDL-induced proliferation of human umbilical vein endothelial cells. *Am J Transl Res.* 2017;9(10):4375-89. PMID 29118901, PMCID PMC5666048.
 18. Zhang H, Bao X, Zhang J, Hu Q, Wei B. Devazepide suppresses cell proliferation and migration, and induces apoptosis in bladder carcinoma. *Transl Androl Urol.* 2021 May;10(5):2113-21. doi: 10.21037/tau-21-409, PMID 34159092, PMCID PMC8185656.
 19. Baldwin GS, Shulkes A. CCK receptors and cancer. *Curr Top Med Chem.* 2007 Jun 1;7(12):1232-8. doi: 10.2174/156802607780960492, PMID 17584144.
 20. Smith JP, Kramer S, Bagheri S. Effects of a high-fat diet and L364,718 on growth of human pancreas cancer. *Dig Dis Sci.* 1990 Jun;35(6):726-32. doi: 10.1007/BF01540175, PMID 2344806.
 21. Zhang X, He C, Wang M, Zhou Q, Yang D, Zhu Y. Structures of the human cholecystokinin receptors bound to agonists and antagonists. *Nat Chem Biol.* 2021 Dec 23;17(12):1230-7. doi: 10.1038/s41589-021-00866-8, PMID 34556863.
 22. Jain AN, Nicholls A. Recommendations for evaluation of computational methods. *J Comput Aided Mol Des.* 2008 Mar 13;22(3-4):133-9. doi: 10.1007/s10822-008-9196-5, PMID 18338228, PMCID PMC2311385.
 23. DwiAgistia D, Purnomo H, Tegar M, Endro Nugroho A. Interaction between active compounds from *Aegle marmelos* correa as anti inflammation agent with COX-1 and COX-2 receptor. Interaction between active compounds from *Aegle marmelos* correa as anti-inflammation with COX-1 and COX-2 receptors. *Traditional Medicine Journal.* 2013;18(2):80-7.
 24. Laksmiani NP, Vidya PNL, Wirasuta MA. *In vitro* and *in silico* antioxidant activity of purified fractions from purple sweet potato ethanolic extract original article. *Int J Pharm Pharm Sci.* 2016;8(8):177-81.
 25. Kurian T. *In silico* screening by molecular docking of heterocyclic compounds with furan or indole nucleus from database for anticancer activity and validation of the method by redocking. *Int J Pharm Pharm Sci.* 2024 Apr 1:42-5. doi: 10.22159/ijpps.2024v16i4.50478.
 26. Guo LD, Chen XJ, Hu YH, Yu ZJ, Wang D, Liu JZ. Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway. *Phytother Res.* 2013 Mar 25;27(3):422-30. doi: 10.1002/ptr.4731, PMID 22628241.
 27. Effendi. *Polarity theory and intermolecular forces.* 2nd ed. Malang: Bayumedia Publishing; 2006. p. 1-290.
 28. Prananta. *Hydrogen bonding.* Malang: Brawijaya University. Brawijaya University; 2013.
 29. Kurniawan Y, Nur M. Modeling study of proton dynamics in hydrogen bonds H₂O one-dimensional solids. *Phys Period.* 2005 Jul;8(3):107-17.
 30. Bare Y. Analysis of phytosterol compounds of *cymbopogon citratus* and *curcuma longa* as antialzheimer's. *Biopendix: Jurnal Biologi, Pendidikan & Terapan.* 2021;7:153-9. doi: 10.30598/biopendixvol7issue2page153-159.
 31. Elfi TN, Bunga YN, Bare Y. *In silico* biological activity study of nonivamide and Nordihydrocapsaicin compounds as anti-inflammatories. *Florea J Biol Learn.* 2021 Nov 25;8(2):82. doi: 10.25273/florea.v8i2.9983.32.
 32. Bare Y, Maulidi A, Sari DR, Tiring SS. *In silico* study predicts the potential of 6-gingerol as an inhibitor of c-Jun N-terminal kinases (JNK). *J Math Sci Netw S.* 2019 Dec 31;1(2):59-63. doi: 10.36873/jjms.v1i2.211.33.
 33. Bare Y, Helvina M, Krisnamurti GC, SM. The potential role of 6-gingerol and 6-shogaol as ACE inhibitors *in silico* study. *Bio.* 2020;8(2):210. doi: 10.24252/bio.v8i2.15704.
 34. Sari DR, Safitri A, Cairns JR, Fatchiyah. Anti-apoptotic activity of anthocyanins has potential to inhibit caspase-3 signaling. *J Trop Life Science.* 2020;10(1):15-25. doi: 10.11594/jtls.10.01.03.
 35. Sari D, Safitri A, Cairns J, Fatchiyah F. Virtual screening of black rice anthocyanins as antiobesity through inhibiting TLR4 and JNK pathway. *J Phys.: Conf Ser.* 2020 Oct 1;1665(1):012024. doi: 10.1088/1742-6596/1665/1/012024.
 36. Krisnamurti GC. Capsaicinoids from *capsicum annum* as an alternative FabH inhibitor of *mycobacterium tuberculosis*: *in silico* study. *Makara J Sci.* 2021 Dec 30;25(4). doi: 10.7454/mss.v25i4.1248.
 37. Sedov IA, Stolov MA, Solomonov BN. Solvophobic effects and relationships between the Gibbs energy and enthalpy for the solvation process. *J Phys Org Chem.* 2011 Nov 14;24(11):1088-94. doi: 10.1002/poc.1859.
 38. Wang X, Liu Y, Xu W, Jia L, Chi D, Yu J. Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. *Drug Deliv Transl Res.* 2021 Oct 15;11(5):2186-97. doi: 10.1007/s13346-020-00884-4, PMID 33452654.
 39. Mathew C, Lal N, SL, TRA, Varkey J. Antioxidant, anticancer and molecular docking studies of novel 5-benzylidene substituted rhodanine derivatives. *Int J Pharm Pharm Sci.* 2023 Jul 1;15(7):7-19. doi: 10.22159/ijpps.2023v15i7.47421.
 40. Ta GC, Mokhtar MB, Peterson PJ, Yahaya NB. A comparison of mandatory and voluntary approaches to the implementation of globally harmonized system of classification and labelling of chemicals (GHS) in the management of hazardous chemicals. *Ind Health.* 2011;49(6):765-73. doi: 10.2486/indhealth.ms1258, PMID 22020020.
 41. Pratt I. Global harmonisation of classification and labelling of hazardous chemicals. *Toxicol Lett.* 2002 Mar;128(1-3):5-15. doi: 10.1016/s0378-4274(01)00529-x, PMID 11869813.
 42. Neag MA, Mocan A, Echeverria J, Pop RM, Bocsan CI, Crişan G. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. *Front Pharmacol.* 2018 Aug 21;9:557. doi: 10.3389/fphar.2018.00557, PMID 30186157, PMCID PMC6111450.
 43. Abushouk AI, Salem AM, Abdel Daim MM. Berberis vulgaris for cardiovascular disorders: a scoping literature review. *Iran J Basic Med Sci.* 2017;20(5):503-10. doi: 10.22038/IJBMS.2017.8674, PMID 28656085, PMCID PMC5478778.
 44. Kysenius K, Brunello CA, Huttunen HJ. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. *Plos One.* 2014 Sep 5;9(9):e107129. doi: 10.1371/journal.pone.0107129, PMID 25192195, PMCID PMC4156429.
 45. Inbaraj JJ, Kukielczak BM, Bilski P, Sandvik SL, Chignell CF. Photochemistry and photocytotoxicity of alkaloids from goldenseal (*Hydrastis canadensis* L.) 1. berberine. *Chem Res Toxicol.* 2001 Nov 1;14(11):1529-34. doi: 10.1021/tx0155247, PMID 11712911.
 46. Pinto Garcia L, Efferth T, Torres A, Hoheisel JD, Youns M. Berberine inhibits cell growth and mediates caspase-independent cell death in human pancreatic cancer cells. *Planta Med.* 2010 Aug 7;76(11):1155-61. doi: 10.1055/s-0030-1249931, PMID 20455200.
 47. Ming M, Sinnett Smith J, Wang J, Soares HP, Young SH, Eibl G. Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. *Plos One.* 2014 Dec 10;9(12):e114573. doi: 10.1371/journal.pone.0114573, PMID 25493642, PMCID PMC4262417.
 48. Park SH, Sung JH, Chung N. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2. *Mol Cell Biochem.* 2014 Sep 4;394(1-2):209-15. doi: 10.1007/s11010-014-2096-1, PMID 24894821.
 49. Park SH, Sung JH, Kim EJ, Chung N. Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines. *Braz J Med Biol Res.* 2015 Feb;48(2):111-9. doi: 10.1590/1414-431X20144293, PMID 25517919, PMCID PMC4321216.

50. Agnarelli A, Natali M, Garcia Gil M, Pesi R, Tozzi MG, Ippolito C. Cell-specific pattern of berberine pleiotropic effects on different human cell lines. *Sci Rep.* 2018 Jul 13;8(1):10599. doi: 10.1038/s41598-018-28952-3, PMID 30006630, PMCID PMC6045596.
51. Liu J, Luo X, Guo R, Jing W, Lu H. Cell metabolomics reveals berberine-inhibited pancreatic cancer cell viability and metastasis by regulating citrate metabolism. *J Proteome Res.* 2020 Sep 4;19(9):3825-36. doi: 10.1021/acs.jproteome.0c00394, PMID 32692565.
52. Tian W, Hao H, Chu M, Gong J, Li W, Fang Y. Berberine suppresses lung metastasis of cancer via inhibiting endothelial transforming growth factor beta receptor 1. *Front Pharmacol.* 2022 Jun 16;13:917827. doi: 10.3389/fphar.2022.917827, PMID 35784732, PMCID PMC9243563.
53. Liu M, Yang Y, Kang W, Liu Y, Tao X, Li X. Berberine inhibits pancreatic intraepithelial neoplasia by inhibiting glycolysis via the adenosine monophosphate -activated protein kinase pathway. *Eur J Pharmacol.* 2022 Jan;915:174680. doi: 10.1016/j.ejphar.2021.174680, PMID 34890544.
54. Fang X, Miao XL, Liu JL, Zhang DW, Wang M, Zhao DD. Berberine induces cell apoptosis through cytochrome C/Apoptotic protease-activating factor 1/caspase-3 and apoptosis-inducing factor pathway in mouse insulinoma cells. *Chin J Integr Med.* 2019 Nov 4;25(11):853-60. doi: 10.1007/s11655-015-2280-5, PMID 26142340.